VYNE Therapeutics to Participate in Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference

Rhea-AI Summary

VYNE Therapeutics Inc. (Nasdaq: VYNE) announced that its President and CEO, David Domzalski, will present at Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference on December 8, 2022. The presentation titled Hit or Miss: Companies with 2023 Readouts & Launches to Keep in Focus will take place from 10:00 to 10:45 a.m. ET. VYNE focuses on innovative therapies for immuno-inflammatory conditions, leveraging its unique bromodomain & extra-terminal (BET) domain platform, including lead programs VYN201 and VYN202.

News Market Reaction – VYNE

+0.66%

+0.66% Session move

In the trading session that priced this news, VYNE gained 0.66%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRIDGEWATER, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer of VYNE, is scheduled to participate in Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference on December 8, 2022.

Panel Presentation Details

Date:	Thursday, December 8, 2022
Time:	10:00 to 10:45 a.m. ET
Panel Presentation:	Hit or Miss: Companies with 2023 Readouts & Launches to Keep in Focus
Presenter:	David Domzalski, President and Chief Executive Officer of VYNE

About VYNE Therapeutics Inc.
VYNE’s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions. The Company’s unique and proprietary bromodomain & extra-terminal (BET) domain platform includes lead programs VYN201 (pan-BETi) and VYN202 (selective-BETi), and access to a library of small molecule BET inhibitors for the potential treatment of immuno-inflammatory conditions licensed from Tay Therapeutics Limited.

For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.

Investor Relations:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com

Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
Tyler.Zeronda@VYNEtx.com

FAQ

What is the date of VYNE's presentation at Cantor Fitzgerald’s conference?

VYNE's presentation is scheduled for December 8, 2022.

Who is presenting for VYNE at the Cantor Fitzgerald conference?

David Domzalski, President and CEO of VYNE, will be presenting.

What is the topic of VYNE's presentation at the conference?

The presentation is titled 'Hit or Miss: Companies with 2023 Readouts & Launches to Keep in Focus'.

What time is VYNE's presentation at the conference?

The presentation will take place from 10:00 to 10:45 a.m. ET.

What therapies is VYNE Therapeutics developing?

VYNE is developing therapies for immuno-inflammatory conditions using its proprietary BET domain platform.